ImmunityBio (IBRX) Treasury Shares (2020 - 2026)

ImmunityBio (IBRX) has reported Treasury Shares for 12 consecutive years, with $5.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Treasury Shares fell 35.63% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $5.9 million (down 35.63% YoY), while the FY2025 annual figure was $8.1 million, up 36.7% from the prior year.
• Treasury Shares eased to $5.9 million in Q1 2026 per IBRX's latest filing, from $8.1 million in the prior quarter.
• Across five years, Treasury Shares topped out at $9.2 million in Q1 2025 and bottomed at $163800.0 in Q4 2023.
• Historically, Treasury Shares has averaged $6.4 million across 5 years, with a median of $6.6 million in 2024.
• Annual changes were most pronounced in 2023 — Treasury Shares tumbled 97.5% — and 2025, when it jumped 4861.95%.
• ImmunityBio's Treasury Shares stood at $6.6 million in 2022, then sank by 97.5% to $163800.0 in 2023, then changed by 0.0% to $163800.0 in 2024, then surged by 4861.95% to $8.1 million in 2025, then decreased by 26.9% to $5.9 million in 2026.
• Business Quant data shows IBRX's Treasury Shares at $5.9 million in Q1 2026, $8.1 million in Q4 2025, and $8.9 million in Q3 2025.